Dany Bell, Rachel Bryce, Rosalia Delfino, Nadia Godin-Heymann, Jessica Horne, Louise Jäger, Michael Jones, Niklas Magnell, Vishali Sharma, David Shera, Marianne J Ratcliffe, Kathy Walls, Rosie Mughal
{"title":"在英国获得指导治疗的生物标志物：癌症患者和医疗保健专业人员的调查。","authors":"Dany Bell, Rachel Bryce, Rosalia Delfino, Nadia Godin-Heymann, Jessica Horne, Louise Jäger, Michael Jones, Niklas Magnell, Vishali Sharma, David Shera, Marianne J Ratcliffe, Kathy Walls, Rosie Mughal","doi":"10.1080/14796694.2025.2535098","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>To understand current barriers to treatment-guiding biomarker testing in cancer patients in the UK.</p><p><strong>Methods: </strong>A literature search, interviews with healthcare professionals, and a focus group of cancer patients were used to identify current challenges and barriers to treatment guiding biomarker testing. These were followed by online surveys of healthcare professionals and patients designed to further explore and quantify challenges to biomarker testing within the UK.</p><p><strong>Results: </strong>Challenges were identified across the entire biomarker testing pathway, the most common being insufficient workforce, long turnaround times, and lack of specific training. These challenges had a negative impact on patient access to targeted cancer therapies.</p><p><strong>Conclusions: </strong>Challenges to accessing treatment-guiding biomarker testing of cancer patients within the UK are impacting clinical decision-making. There is a requirement to improve awareness and training of healthcare professionals, particularly nurses and advanced clinical practitioners, with opportunities to improve outdated and fragmented ordering and reporting processes. Steps should also be taken to improve the availability of plain-language information materials for patients, to promote understanding and self-advocacy.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2625-2636"},"PeriodicalIF":2.6000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344809/pdf/","citationCount":"0","resultStr":"{\"title\":\"Access to treatment-guiding biomarkers in the UK: surveys of cancer patients and healthcare professionals.\",\"authors\":\"Dany Bell, Rachel Bryce, Rosalia Delfino, Nadia Godin-Heymann, Jessica Horne, Louise Jäger, Michael Jones, Niklas Magnell, Vishali Sharma, David Shera, Marianne J Ratcliffe, Kathy Walls, Rosie Mughal\",\"doi\":\"10.1080/14796694.2025.2535098\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>To understand current barriers to treatment-guiding biomarker testing in cancer patients in the UK.</p><p><strong>Methods: </strong>A literature search, interviews with healthcare professionals, and a focus group of cancer patients were used to identify current challenges and barriers to treatment guiding biomarker testing. These were followed by online surveys of healthcare professionals and patients designed to further explore and quantify challenges to biomarker testing within the UK.</p><p><strong>Results: </strong>Challenges were identified across the entire biomarker testing pathway, the most common being insufficient workforce, long turnaround times, and lack of specific training. These challenges had a negative impact on patient access to targeted cancer therapies.</p><p><strong>Conclusions: </strong>Challenges to accessing treatment-guiding biomarker testing of cancer patients within the UK are impacting clinical decision-making. There is a requirement to improve awareness and training of healthcare professionals, particularly nurses and advanced clinical practitioners, with opportunities to improve outdated and fragmented ordering and reporting processes. Steps should also be taken to improve the availability of plain-language information materials for patients, to promote understanding and self-advocacy.</p>\",\"PeriodicalId\":12672,\"journal\":{\"name\":\"Future oncology\",\"volume\":\" \",\"pages\":\"2625-2636\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344809/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14796694.2025.2535098\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/8 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2535098","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Access to treatment-guiding biomarkers in the UK: surveys of cancer patients and healthcare professionals.
Aims: To understand current barriers to treatment-guiding biomarker testing in cancer patients in the UK.
Methods: A literature search, interviews with healthcare professionals, and a focus group of cancer patients were used to identify current challenges and barriers to treatment guiding biomarker testing. These were followed by online surveys of healthcare professionals and patients designed to further explore and quantify challenges to biomarker testing within the UK.
Results: Challenges were identified across the entire biomarker testing pathway, the most common being insufficient workforce, long turnaround times, and lack of specific training. These challenges had a negative impact on patient access to targeted cancer therapies.
Conclusions: Challenges to accessing treatment-guiding biomarker testing of cancer patients within the UK are impacting clinical decision-making. There is a requirement to improve awareness and training of healthcare professionals, particularly nurses and advanced clinical practitioners, with opportunities to improve outdated and fragmented ordering and reporting processes. Steps should also be taken to improve the availability of plain-language information materials for patients, to promote understanding and self-advocacy.
期刊介绍：
Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.
The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
